Media Centre
Latest press releases
-
Tagrisso with the addition of chemotherapy approved in China as 1st-line treatment for patients with EGFR-mutated advanced lung cancer
-
Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer
-
Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small cell lung cancer
-
Imfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
-
Imfinzi plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.